Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China

被引:7
|
作者
Nie, Jing [1 ]
Wu, Huina [1 ]
Sun, Lei [1 ]
Ding, Yanjiao [1 ]
Luan, Yepeng [2 ]
Wu, Jiyong [1 ]
机构
[1] Shandong Second Prov Gen Hosp, Dept Pharm, Jinan, Shandong, Peoples R China
[2] Qingdao Univ, Med Coll, Sch Pharm, Dept Med Chem, Qingdao, Shandong, Peoples R China
关键词
fuzuloparib; niraparib; olaparib; cost-effectiveness; maintenance treatment; ovarian cancer; BRCA1/2; mutation; THERAPY; CANCER; TRIALS;
D O I
10.3389/fphar.2022.987337
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Maintenance therapy with the poly (ADP-ribose) polymerase inhibitors (PARPis) for platinum-sensitive recurrent ovarian carcinoma (OC) have proven to be effective compared with placebo. We aimed to evaluate the cost-effectiveness (CE) of maintenance fuzuloparib compared to routine surveillance (RS), niraparib and olaparib for platinum-sensitive recurrent OC from the Chinese healthcare systems.Method: A partitioned survival model with three-state (progression-free, progressed, death) was constructed utilizing TreeAge Pro 2011 software to evaluate the economic value of fuzuloparib, niraparib and olaparib maintenance treatment for platinum-sensitive recurrent OC based on the clinical data derived from FZOCUS-2, ENGOT-OV16/NOVA and ENGOT-Ov21/SOLO2. Transition probabilities were estimated from the reported survival probabilities in those trials. Cost and health preference data were derived from the literature. The quality-adjusted life-years (QALYs) and lifetime costs were measured for this analysis. A 5 years horizon and 5%/year discount rates were used. One-way analysis, and probabilistic sensitivity analysis (PSA) were performed to explore the model uncertainties.Results: Total cost of fuzuloparib, niraparib and olaparib were $31628.10, $48183.48 and $54605.54, whereas they had an incremental cost-utility ratio of $31992.69, $32216.08 and $23359.26 per additional progression-free survival (PFS) QALYs gained compared with RS, relatively. Model showed that maintenance fuzuloparib achieved at least an 85.5% probability of CE at the threshold of $37654.50/QALY. One-way sensitivity analysis revealed that the results were sensitive to the PFS and the price of medicines.Conclusion: Fuzuloparib was less cost-effective for patients with germline BRCA1/2 mutation and platinum-sensitive recurrent OC compared to olaparib, but was superior to niraparib from the Chinese healthcare systems perspective.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Cost-effectiveness of BRCA1/2 mutation profiling to target olaparib use in patients with metastatic breast cancer
    Saito, Shota
    Nakazawa, Kyoko
    Nagahashi, Masayuki
    Ishikawa, Takashi
    Akazawa, Kouhei
    PERSONALIZED MEDICINE, 2019, 16 (06) : 439 - 448
  • [42] Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial
    Pignata, Sandro
    Oza, Amit
    Hall, Geoff
    Pardo, Beatriz
    Madry, Radoslaw
    Cibula, David
    Klat, Jaroslav
    Montes, Ana
    Glasspool, Rosalind
    Colombo, Nicoletta
    Pete, Imre
    Ibanez, Ana Herrero
    Marin, Margarita Romeo
    Ilieva, Rumyana
    Timcheva, Constanta
    Di Maio, Massimo
    Blakeley, Christopher
    Taylor, Rosie
    Barnicle, Alan
    Clamp, Andrew
    GYNECOLOGIC ONCOLOGY, 2023, 172 : 121 - 129
  • [43] Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
    Lee, Jung-Min
    Moore, Richard G.
    Ghamande, Sharad
    Park, Min S.
    Diaz, John P.
    Chapman, Julia
    Kendrick, James
    Slomovitz, Brian M.
    Tewari, Krishnansu S.
    Lowe, Elizabeth S.
    Milenkova, Tsveta
    Kumar, Sanjeev
    Dymond, Mike
    Brown, Jessica
    Liu, Joyce F.
    CLINICAL CANCER RESEARCH, 2022, 28 (19) : 4186 - 4193
  • [44] Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
    Majic, Ana
    Mise, Branka Petric
    Matkovic, Visnja
    Belac Lovasic, Ingrid
    Katic, Kristina
    Canjko, Ivana
    Frobe, Ana
    Bajic, Zarko
    Vrdoljak, Eduard
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [45] OLAPARIB IN THE MAINTENANCE TREATMENT OF PLATINUM-SENSITIVE RELAPSE OF BRCA MUTANT OVARIAN CANCER IN ROUTINE CLINICAL PRACTICE. FIRST RESULTS OF OBSERVATIONAL STUDY IN RUSSIAN PATIENTS
    Artamonova, E.
    Kovalenko, E.
    Snegovoy, A.
    Kononenko, I.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 628 - 629
  • [46] Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial
    Poveda Velasco, A. M.
    Lheureux, S.
    Colombo, N.
    Cibula, D.
    Elstrand, M.
    Weberpals, J.
    Bjurberg, M.
    Oaknin, A.
    Sikorska, M.
    Gonzalez Martin, A. J.
    Madry, R.
    Rubio Perez, M. J.
    Ledermann, J. A.
    Ozgoren, O.
    Barnicle, A.
    Marshall, H.
    Bashir, Z.
    Skof, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S790 - S790
  • [47] Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer (vol 19, e0301271, 2024)
    Mehra, Tarun
    Lupatsch, Judith E.
    Koessler, Thibaud
    Dedes, Konstantin
    Siebenhuener, Alexander Reinhard
    von Moos, Roger
    Wicki, Andreas
    Schwenkglenks, Matthias E.
    PLOS ONE, 2024, 19 (12):
  • [48] COST-EFFECTIVENESS OF BRCA1/2 MUTATION PROFILING TO TARGET OLAPARIB USE IN PATIENTS WITH METASTATIC BREAST CANCER IN JAPAN
    Saito, S.
    Nakazawa, K.
    Nagahashi, M.
    Akazawa, K.
    VALUE IN HEALTH, 2018, 21 : S40 - S40
  • [49] Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.
    Lee, Jung-min
    Moore, Richard G.
    Ghamande, Sharad A.
    Park, Min S.
    Diaz, John Paul
    Chapman, Julia A.
    Kendrick, James Erasmus
    Slomovitz, Brian M.
    Tewari, Krishnansu Sujata
    Lowe, Elizabeth S.
    Milenkova, Tsveta
    Kumar, Sanjeev
    Dymond, Mike
    Kozarewa, Iwanka
    Liu, Joyce F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain
    Delgado-Ortega, Laura
    Gines Rubio, Jordi
    Carmen de Espana, Maria del Carmen
    Carcedo, David
    Cordero Puentes, Luis
    Moya de Alarcon, Carlota
    FARMACIA HOSPITALARIA, 2018, 42 (03) : 95 - 102